Vaccine

Vaccine

Break in cold chain mainly results in:

Break in cold chain defined as temperature excursion outside recommended range due to equipment failure, power outage, improper conditioning of ice packs causing freezing, transport delays, human error leaving vaccines outside refrigerator. Consequences mainly vaccine failure due to irreversible potency loss. Heat exposure accelerates physico-chemical degradation: proteins unfold aggregating via hydrophobic interactions, deamidation of asparagine residues altering epitopes, hydrolysis of phosphodiester bonds in mRNA vaccines producing fragmented inactive RNA, replication titer of live attenuated vaccines drops logarithmically losing ability to induce immunity, toxoids dissociate from aluminum adjuvant losing depot effect. Freezing aluminum-adjuvanted vaccines causes aluminum salts to agglomerate forming large crystals visible as granular sediment after shake test failing, reducing surface area and adjuvanticity causing injection site abscess. Once potency lost cannot be restored by returning to cold chain because degradation covalent. Administration of compromised vaccine yields seronegativity, primary vaccine failure documented outbreaks despite high documented coverage, as observed with measles resurgence investigation tracing to frozen DTP hepatitis B carriers causing no seroconversion, requiring costly revaccination campaigns, mistrust, loss of herd immunity threshold, morbidity mortality. Therefore strict compliance and VVM monitoring vital to discard affected vials immediately preventing ineffective immunization.

Ref: Matthias et al. Bull WHO 2007 85:400 Break cold chain vaccine failure; WHO VVM guidance.

View Details

Vaccine

The cold chain in vaccination refers to:

Cold chain in vaccination encompasses system ensuring vaccines maintained within manufacturer recommended temperature range during storage and transport from production facility through national, regional, district stores to health centers and outreach vaccination sessions preserving potency until moment administration. Term refers to low temperature preservation, not manufacturing or injection method. Typical vaccines requiring 2 to 8C refrigeration include DTP, hepatitis B, pentavalent, IPV, BCG; some lyophilized vaccines stable at ambient during transport but reconstituted require immediate use; ultracold chain minus 60 to 80C required for Pfizer BioNTech mRNA and minus 20C Moderna needing specialized freezers, dry ice shippers. Infrastructure comprises walk-in cold rooms with standby generators, ice-lined refrigerators maintaining holdover 16 hours without electricity, refrigerated trucks with data loggers recording temperature every 5 minutes, cold boxes with conditioned ice packs frozen at minus 20 then conditioned to 0C preventing freezing aluminum adjuvanted vaccines, vaccine carriers with foam insulation for daily outreach preserving temperature 24 hours. Continuous monitoring via 30 day electronic loggers, vaccine vial monitors VVM chemical labels indicating cumulative heat exposure via color change, freeze indicators for freeze sensitive vaccines, and standard operating procedures handling stock management ensure potency. Breaks cause costly wastage and vaccine failure undermining trust.

Ref: WHO Cold chain storage transport low temperature 2-8C; WHO PQS devices catalog; CDC storage.

View Details

Vaccine

BCG vaccine is administered via:

BCG vaccine is administered via intradermal route which is uniquely specified among routine childhood immunizations. Technique involves injection of small volume 0.05 ml for infants under 12 months and 0.1 ml for older children into superficial dermis of lower insertion of deltoid muscle left arm using 26G or 27G needle inserted bevel upward at approximately 10-15 degree angle pushing needle 2 mm subepidermal creating characteristic peau d orange wheal 6-8 mm bleb that disappears within 30 minutes indicating correct placement. Dermis abundant in Langerhans cells expressing langerin CD207 and dermal CD14+ dendritic cells highly efficient capturing mycobacterial antigens Ag85 complex, migrating to axillary lymph nodes priming Th1 cells secreting interferon gamma activating macrophages forming granuloma containment. Intramuscular or subcutaneous misadministration risks cold abscess formation caseous necrosis, suppurative lymphadenitis, dissemination in immunocompromised and absence of scar considered marker of take. Intradermal route ensures slow depot release, localized induration 2-3 weeks later forming papule ulceration healing with flat 3-7 mm scar visible for life. WHO recommends only intradermal, discouraging jet injectors; training with orange peel simulation and competency assessment mandatory to ensure high coverage scar rates above 90 percent monitoring program quality.

Ref: WHO BCG vaccine position paper 2018 intradermal; Plotkin BCG route; CDC intradermal.

View Details

Vaccine

Edible vaccines should preferably be consumed:

Edible vaccines rely on oral exposure to gut associated lymphoid tissue, so preservation of antigen structural integrity is crucial. Cooking, drying at high temperature, roasting, fermentation involving microbial proteases and acidic boiling denatures protein tertiary structure, unfolding alpha helices and beta sheets, disrupting disulfide bonds essential for conformational B cell epitopes required for neutralizing antibody induction, aggregating proteins into insoluble forms, destroying T cell epitopes via hydrolysis. For example HBsAg virus like particles dissociate into monomers losing particulate presentation critical for B cell receptor crosslinking if heated above 60C. Maillard reaction between sugars and lysine alters antigenicity. Therefore transgenic expression targeted to raw edible tissues like banana fruit pulp eaten fresh peeled, tomato fruit consumed raw in salads, lettuce leaves, baby carrots, rice seeds eaten without extensive heating although rice normally cooked may retain some antigen if heat stable variants engineered. If cooking mandatory, alternative freeze-drying retaining structure followed by consumption as powder capsules or incorporation into chocolate considered. Guidance emphasizes consumption raw without processing after harvest with minimal refrigeration to maintain native conformation for maximal mucosal IgA and avoid tolerance.

Ref: Mason et al. 2002 Trends Biotech Edible consumption raw; Streatfield Kwon 2007 Should be raw.

View Details

Vaccine

Which plant was engineered to produce edible Hepatitis B vaccine?

Banana was specifically engineered to produce edible Hepatitis B vaccine demonstrating fruit-based oral immunization feasibility. Hepatitis B surface antigen HBsAg 226 amino acid small surface protein self-assembles into 22 nm virus like particles highly immunogenic protective against HBV infection. Early work by Thanavala 1995 expressed HBsAg in transgenic tobacco plants showing assembly. Subsequent collaboration by Arntzen, Mason and colleagues introduced HBsAg gene under fruit specific promoter E8 and constitutive CaMV 35S with endoplasmic reticulum retention signal KDEL into Cavendish banana AAA group via Agrobacterium mediated transformation of embryogenic cell suspensions and regeneration through somatic embryogenesis, slow process due to triploid sterility and generation time 12-18 months. Transgenic banana fruits accumulated HBsAg up to 0.05 percent total soluble protein in pulp, sufficient to elicit anti HBs IgG when orally consumed in mice after feeding peeled fruit, boosting after parenteral priming. Banana advantages include palatability raw without cooking preserving heat labile VLP structure, eaten by infants and children, perennial high yield in tropical regions where hepatitis B endemic, no requirement for cooking that denatures antigens, and cultural acceptance. Limitations low expression variability and delayed fruiting pushed platform toward lettuce and maize seeds, but banana remains iconic proof concept for edible.

Ref: Thanavala et al. PNAS 1995 92:3358 Banana HBsAg; Arntzen 1997 Edible Hepatitis B banana; Lancet.

View Details

Vaccine

Edible vaccines are produced using:

Edible vaccines utilize transgenic plants as low-cost production and oral delivery systems synthesizing recombinant immunogens in edible tissues. Concept pioneered by Charles Arntzen 1990 proposing foods containing antigens could be eaten eliminating purification, cold chain, sterile needles, medical personnel and hazardous waste associated with injections. Plant transformation via Agrobacterium tumefaciens binary vector carrying antigen gene driven by constitutive CaMV 35S promoter or tissue specific patatin, glutelin for seed accumulation, plus signal peptide targeting to endoplasmic reticulum for glycosylation and stability. Plants such as potato, tomato, lettuce, rice, banana accumulate antigen at 0.01-0.3 percent total soluble protein in leaves tubers fruits seeds. Bioencapsulation within plant cell wall composed of cellulose lignin protects antigen from gastric acidic pH 1-2 and pepsin digestion until arrival in small intestine where gut microbiota cellulases degrade wall releasing antigen near Peyer's patches M cells that translocate antigen to underlying dendritic cells initiating mucosal IgA and systemic IgG. Advantages include scalability agriculture hectares, oral tolerance risk if dose too low causing regulatory T cell induction, and need for dose standardization fruit size variability challenges. Nonetheless plant made vaccines promise for livestock and developing regions.

Ref: Ma et al. Nat Rev Genet 2003 Plant vaccines; Rybicki Adv Virus Res 2014 Edible transgenic.

View Details

Vaccine

DNA vaccines deliver genes in the form of:

DNA vaccines deliver genetic instructions as circular plasmid DNA rather than protein antigen or RNA. Plasmid constructs typically contain bacterial origin pUC, antibiotic resistance for selection during manufacturing, and eukaryotic expression cassette comprising strong promoter cytomegalovirus CMV immediate early with intron A enhancing transcription, codon optimized antigen gene, polyadenylation signal bovine growth hormone BGH or SV40 preventing mRNA degradation. Plasmids produced in Escherichia coli fermentation high copy number, purified supercoiled isoform removing endotoxin via chromatography. Upon intramuscular delivery with electroporation needles delivering brief electrical pulses increasing membrane permeability or needle free jet injector, plasmid enters myocytes and antigen presenting cells, translocates nucleus independently of cell division, transcribed by RNA polymerase II into mRNA exported then translated. Resulting antigen triggers both humoral and cellular immunity. Advantages include exceptional thermostability stable at room temperature months facilitating transport without stringent cold chain, simple large scale manufacturing, lack of anti-vector immunity permitting homologous boosting, ability to encode multiple antigens single plasmid. Limitations include relatively low transfection efficiency in humans requiring devices, theoretical rare integration at frequencies less than 10^-7 per plasmid. World's first approved ZyCoV-D COVID DNA vaccine India uses three dose regimen.

Ref: Wolff et al. Science 1990 DNA vaccines plasmid; Plotkin DNA vaccines; WHO DNA plasmid.

View Details

Vaccine

Which of the following is an mRNA vaccine?

Pfizer-BioNTech BNT162b2 Comirnaty exemplifies messenger RNA vaccine success. It contains 30 microgram dose of nucleoside modified mRNA encoding full length SARS-CoV-2 spike protein stabilized in prefusion conformation by double proline substitution K986P V987P preventing post fusion transition, retaining epitopes for neutralizing antibodies. mRNA produced by cell free transcription, purified to remove dsRNA impurities that trigger innate over activation. LNP formulation enables efficient transfection without electroporation. After emergency use authorization December 2020, phase three trial in 43,000 participants demonstrated 95 percent efficacy against symptomatic COVID-19 confirmed by RT-PCR and 100 percent against severe disease initially. Unlike Covaxin whole virion inactivated requiring BSL-3 production, Covishield chimpanzee adenovirus vector, BCG live mycobacterial tuberculosis vaccine unrelated to COVID, Comirnaty mRNA platform demonstrates synthetic biology rapid response with manufacturing cycle weeks versus months. Cold chain ultralow freezer minus 80C required initially due to RNA lability but later stability data supported minus 20C and 2-8C thawed short term. Subsequent bivalent versions encoding Omicron BA.4-5 spike illustrate adaptability updating coding sequence while keeping LNP chemistry identical for future pandemics.

Ref: Polack et al. NEJM 2020 383:2603 Pfizer-BioNTech mRNA; CDC mRNA vaccines list; FDA Comirnaty.

View Details

Vaccine

mRNA vaccines work by:

Messenger RNA vaccines represent nucleic acid platform delivering synthetic mRNA encoding pathogen antigen directly to host cytoplasm where host ribosomal machinery translates it transiently. Manufacturing involves in vitro transcription using T7 RNA polymerase from linearized plasmid DNA template encoding spike protein, incorporation of modified nucleoside N1 methylpseudouridine replacing uridine reducing TLR7 mediated inflammation and increasing translation half-life, addition of 5' cap 7-methylguanosine via vaccinia capping enzyme and 2'O-methylation, and 3' polyadenine tail 100 nt for stability. mRNA encapsulated in lipid nanoparticles LNP composed of ionizable lipid ALC-0315 or SM-102 protonated at low pH encapsulating RNA, helper lipid DSPC forming bilayer, cholesterol fluidity, and PEGylated lipid reducing aggregation and prolonging circulation. Upon intramuscular injection LNPs fuse with cell membrane or endocytosed, ionizable lipid becomes cationic at endosomal low pH disrupting endosome releasing mRNA to cytosol. Ribosomes translate antigen protein undergoing post translational modifications, secreted or membrane anchored, processed for MHC I and II presentation inducing neutralizing IgG and CD4 Th1 and CD8 cytotoxic memory. mRNA degraded within days by RNases no integration risk enabling rapid design.

Ref: Pardi et al. Nat Rev Drug Discov 2018 mRNA mechanism; Polack NEJM mRNA; CDC mRNA work.

View Details

Vaccine

AZD1222 (Covishield) vaccine uses which vector?

AZD1222 vaccine known in India as Covishield produced by Serum Institute Pune under license from AstraZeneca Oxford University uses chimpanzee adenovirus vector ChAdOx1. ChAdOx1 derived from chimpanzee adenovirus isolate Y25 taken from chimp stool 1960s, selected because human population seroprevalence low compared to human adenovirus 5 where 40-60 percent adults have neutralizing antibodies compromising vector. Vector engineered by deleting E1 genes essential for replication making it replication deficient incapable of causing disease, requiring E1 complementing cells HEK293 for manufacturing, and deleting E3 region enhancing immunogenicity and cloning capacity. SARS-CoV-2 spike gene codon optimized full length with leader sequence tPA inserted under CMV immediate early promoter in E1 locus. After injection vector enters cells via CAR receptor, traffics to nucleus, does not integrate, transcribes spike mRNA, translates spike glycoprotein expressed on cell surface in prefusion conformation triggering anti spike IgG neutralizing RBD binding ACE2, Th1 biased CD4 response and cytotoxic CD8. Clinical trials showed 70-90 percent efficacy against severe disease, easy storage at 2-8C suiting low income countries, distinguishing from human adenovirus 5 vector Sputnik. Thus chimpanzee adenovirus chosen to avoid anti-vector immunity.

Ref: Voysey Lancet 2021 397:881 AZD1222 ChAdOx1; Oxford ChAdOx1 history; WHO Covishield.

View Details

Vaccine

Viral vector vaccines deliver antigen genes using:

Viral vector vaccines deliver genes encoding pathogen antigens using harmless viruses engineered to be replication deficient as transportation vehicles. Concept employs vector virus lacking pathogenic genes but retaining ability to infect mammalian cells, deliver DNA into nucleus, transcribe transgene using host polymerase, translate antigen intracellularly mimicking natural infection. Vector backbone commonly human adenovirus serotypes 5 and 26, chimpanzee adenovirus ChAdOx1, canarypox ALVAC, modified vaccinia Ankara MVA, vesicular stomatitis virus VSV, adeno associated virus. Deletion of E1 locus renders adenovirus unable to replicate except in complementing HEK293 cells, E3 deletion increases packaging capacity to 7-8 kb insert. Upon intramuscular injection vector transduces myocytes and dendritic cells, antigen peptides presented on MHC I to CD8 T cells and secreted antigen captured for MHC II to CD4, generating strong humoral and cellular immunity without need exogenous adjuvant because vector components trigger innate sensors TLR9 detecting dsDNA, cGAS STING. Pre-existing immunity to human adenovirus can impair efficacy, mitigated using rare serotypes or chimpanzee vectors low seroprevalence. Platform proved successful for Ebola Ad26 ZEBOV, COVID-19 AstraZeneca and Janssen vaccines demonstrating rapid adaptability.

Ref: Tatsis Ertl Mol Ther 2004 Viral vectors; Draper Heeney Nat Rev Microbiol Vector vaccines.

View Details

Vaccine

DPT vaccine provides protection against:

DPT vaccine, also known as triple antigen, provides simultaneous protection against diphtheria, pertussis, tetanus three bacterial diseases responsible for high childhood morbidity mortality before immunization era. Diphtheria caused by Corynebacterium diphtheriae toxigenic strains producing diphtheria toxin transported to heart causing myocarditis, nerves neuritis and kidney necrosis plus pseudomembrane airway obstruction. Pertussis caused by Bordetella pertussis Gram-negative coccobacillus attaching ciliated epithelium via filamentous hemagglutinin, producing pertussis toxin ADP-ribosylating Gi proteins disrupting signaling causing lymphocytosis and paroxysmal cough apnea in infants. Tetanus caused by Clostridium tetani anaerobic spore forming bacterium in soil, producing tetanospasmin blocking glycine release causing spastic paralysis and respiratory failure mortality 80 percent without ICU. DPT contains diphtheria toxoid, tetanus toxoid, whole-cell killed pertussis wP or purified acellular aP antigens adsorbed. Simultaneous administration induces antitoxin antibodies neutralizing diphtheria and tetanus toxins and antibacterial antibodies against Bordetella preventing colonization. Schedule 6,10,14 weeks plus boosters ensures protection persisting into childhood, boosters DTaP at 15-18 months and Tdap adolescence due to waning pertussis immunity.

Ref: CDC Pink Book Diphtheria Pertussis Tetanus DPT; WHO DPT definition combined; Plotkin.

View Details